Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Operating Expenses: 2021-2024

Historic Other Operating Expenses for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to $12.8 million.

  • Tarsus Pharmaceuticals' Other Operating Expenses rose 156.29% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 170.77%. This contributed to the annual value of $12.8 million for FY2024, which is 705.15% up from last year.
  • Tarsus Pharmaceuticals' Other Operating Expenses amounted to $12.8 million in FY2024, which was up 705.15% from $1.6 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Other Operating Expenses registered a high of $12.8 million during FY2024, and its lowest value of $955,000 during FY2022.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Other Operating Expenses value was $1.6 million (recorded in 2023), while the average stood at $5.1 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Other Operating Expenses crashed by 53.98% in 2022 and then spiked by 705.15% in 2024.
  • Yearly analysis of 4 years shows Tarsus Pharmaceuticals' Other Operating Expenses stood at $2.1 million in 2021, then crashed by 53.98% to $955,000 in 2022, then spiked by 66.81% to $1.6 million in 2023, then spiked by 705.15% to $12.8 million in 2024.